QuidelOrtho's fundamentals remain under pressure, with revenue stagnating at roughly $620-700M per quarter and gross margin compressing from 49.6% in Q1 2025 to 43.3% in Q2 2026. The company has posted net losses in nine of the last ten quarters, including a -...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $0.13+366.2% vs -$0.05 | $631M+2.0% vs $619M |
Q2 2026 May 5, 2026 | -$0.04-110.8% vs $0.37 | $620M-6.8% vs $665M |
Q1 2026 Feb 11, 2026 | $0.46+7.0% vs $0.43 | $724M+3.3% vs $701M |
Q4 2025 Nov 5, 2025 | $0.80+56.9% vs $0.51 | $700M+4.6% vs $669M |
Squarepoint Ops LLC acquired a new position in QuidelOrtho Corporation (NASDAQ: QDEL) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 85,251 shares of the company's stock, valued at approximately $1,493,000. Squarepoint Ops LLC owned 0.12% of QuidelOrtho as of
SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference. Hosted by Stephanie Kleewein, the special episode showcases three presentations addressing some of healthcare's most pressing challenges: delivering faster molecular diagnostic results, improving antibiotic stewardship and accelerating cardiovascular assessment.
QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.
QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.
Benchmark QDEL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for QuidelOrtho Corporation (QDEL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.34 | $705.09M | -0.62 | -1.89% | -41.45% | -46.15% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — | |
| $378.88 | $10.2B | 13.59 | 0.65% | 8.59% | 3.15% | — | |
| $13.57 | $2.95B | -339.25 | -2.71% | -0.91% | -0.37% | — | |
| $522.02 | $41.18B | 39.91 | 10.42% | 25.03% | 71.96% | — | |
| $148.17 | $10.61B | 26.22 | 0.9% | 9.99% | 10.09% | — |
QuidelOrtho Corporation (QDEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
QuidelOrtho Corporation (QDEL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 23, 2026·SEC
Jun 16, 2026·SEC
Get notified when QDEL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
QuidelOrtho Corporation (QDEL) stock FAQ — growth, dividends, profitability & financials explained
QuidelOrtho Corporation (QDEL) reported $2.67B in revenue for fiscal year 2025. This represents a 7651% increase from $34.5M in 1995.
QuidelOrtho Corporation (QDEL) saw revenue decline by 1.9% over the past year.
QuidelOrtho Corporation (QDEL) reported a net loss of $1.05B for fiscal year 2025.
QuidelOrtho Corporation (QDEL) has a return on equity (ROE) of -46.1%. Negative ROE indicates the company is unprofitable.
QuidelOrtho Corporation (QDEL) had negative free cash flow of $171.0M in fiscal year 2025, likely due to heavy capital investments.
